scispace - formally typeset
R

Ryohei Watanabe

Researcher at Toho University

Publications -  41
Citations -  408

Ryohei Watanabe is an academic researcher from Toho University. The author has contributed to research in topics: Cancer & Laparoscopic surgery. The author has an hindex of 8, co-authored 41 publications receiving 360 citations.

Papers
More filters
Journal ArticleDOI

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

TL;DR: It is suggested that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa, and the levels of inflammatory cytokines in blood and liver were significantly lower inphage-treated mice than in phage-untreated mice.
Journal ArticleDOI

KL-6 is another useful marker in assessing a micropapillary pattern in carcinomas of the breast and urinary bladder, but not the colon

TL;DR: It is suggested that KL-6 is a useful marker to assess the MP character of breast and urinary bladder carcinomas; that MUC1 was similarly positive, with the addition of cytoplasmic positivity in some cases; and that the MP pattern of colon cancer, positive for CD 10, was different in character from both breast and bladder cancers, although all these cancers seemingly exhibit similar MP patterns on histopathology.
Journal ArticleDOI

Neutrophil/lymphocyte ratio has a prognostic value for patients with terminal cancer

TL;DR: Neutrophil/lymphocyte ratio appears to be a useful and simple parameter to predict the clinical outcomes of patients with terminal cancer.
Journal ArticleDOI

Osteoclast-like Giant Cell Tumor of the Pancreas with Metastases to Gallbladder and Lymph Nodes : A Case Report

TL;DR: Findings clearly suggest that mononuclear cells are capable of differentiation and proliferation and may have been the only true tumor cells in this neoplasm, and that OGCs may have was a paraneoplastic product of this rare tumor.
Journal ArticleDOI

Isolated bacteria and drug susceptibility associated with the course of surgical site infections

TL;DR: New broad-spectrum antibiotics such as carbapenems should not be selected for the treatment of early-phase surgical site infections, because of the increase in drug-resistant bacteria.